PresentationHey, everyone. Welcome to our next session with Curis. My name is Li Watsek, a biotech analyst here at Cantor. I'm very pleased to have Jim Dentzer, CEO of Curis, with us today. Maybe start, I'll just hand it over to Jim to give us some quick overview.James DentzerPresident, CEO, Secretary, Treasurer & Director Thank you. I appreciate it, and thank you for having me. Yes, the overview of Curis is we're really at an exciting crossroads. So we've got one drug that we're funding. We've got a pretty ...